Where is BiGEN located?

BiGEN is headquartered in Goyang, South Korea.

Is BiGEN a funded company?

BiGEN is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does BiGEN rank among its competitors?

BiGEN ranks 60th amongst 98 active competitors, of which 7 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was MindBio Therapeutics, which secured an undisclosed amount in Apr, 2026.

Who are the top competitors of BiGEN?

BiGEN's top competitors include Altasciences, HMR London and Celerion. Among them, MindBio Therapeutics secured the most recent funding round in April, 2026.

BiGEN - 2026 Company Profile & Competitors

Most viewed in 2019

BiGEN is an unfunded company based in Goyang (South Korea), founded in 2015. It operates as a Provider of early stage clinical development services. BiGEN has not raised any funding yet. The company has 98 active competitors, including 7 funded and 23 that have exited. Its top competitors include companies like Altasciences, HMR London and Celerion.

Key Metrics

Founded Year

2015

Location

Goyang, South Korea

Stage

Unfunded

Ranked

60^th among 98 active competitors

Investment & Acquisitions

Noile-Immune Biotech & 1 more

Similar Companies

Altasciences & 117 more

View BiGEN's full profile

BiGEN has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BiGEN include Altasciences, HMR London and Celerion. Here is the list of Top 10 competitors of BiGEN, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Altasciences 2015, Laval (Canada), Acquired	Early phase CRO	-	Signet Healthcare Partners, Apollo Investment Corporation ... & 1 others	52/100
2nd	HMR London 1993, London (United Kingdom), Acquired	Provider of early phase clinical research services for drug development	-	EIC Fund, Europa	51/100
3rd	Celerion 2010, Lincoln (United States), Acquired	Translational medicine experts accelerating drug development for global patient impact	-	Bain Capital Ventures, SV Health Investors ... & 4 others	51/100
4th	MindBio Therapeutics 2021, Melbourne (Australia), Public	Provider of phase I & II clinical trial services for mental health diseases	-	Blackhawk Growth Corp, Hardenbrook Group	48/100
5th	AWAKN 2020, Portishead (United Kingdom), Acquired	CRO focused on early stage clinical trial research	-	Palo Santo, Iter Investments	47/100
6th	BioPharma Services 2006, Toronto (Canada), Acquired	Provider of early stage clinical trial services	-	-	46/100
7th	Avance Clinical 2018, Thebarton (Australia), Late Stage	Provider of clinical development services	-	Riverside, Genesis Capital	43/100
8th	Aditum Bio 2019, Oakland (United States), Unfunded	CRO focused on clinical trial on phase II studies	-	-	42/100
9th	iCardiac Technologies 2006, Rochester (United States), Acquired	Company offering core laboratory services mainly for cardiac safety testing and respiratory diseases	$4M	Stonehenge Growth Equity Partners, Norwest ... & 4 others	41/100
10th	Unravel Biosciences 2020, Boston (United States), Seed	CRO offering early stage clinical development of drugs	$500K	BoxOne Ventures, Beresford Ventures	41/100
60th	BiGEN 2015, Goyang (South Korea), Unfunded	Provider of early stage clinical development services	-	-	20/100